HOME >> MEDICINE >> NEWS
Study examines three-day antibiotic regimens for treating bladder infection in women

CHICAGO A three-day regimen of the antibiotic amoxicillin-clavulanate is not as effective as ciprofloxacin at treating an uncomplicated bladder infection in women, according to a study in the February 23 issue of JAMA.

Acute uncomplicated urinary tract infections (UTIs) are among the most commonly encountered bacterial infections in women, according to background information in the article. Management of these infections has been made more complicated in recent years by increasing antimicrobial resistance, which has led to increased use of alternative antibiotics. There have been no published studies on the efficacy of one such antibiotic, amoxicillin-clavulanate, in the treatment of acute cystitis (inflammation of the urinary bladder) in the current era of high-level amoxicillin resistance.

Thomas M. Hooton, M.D., of the University of Washington and Harborview Medical Center, Seattle, and colleagues conducted a randomized trial that compared 3-day regimens of amoxicillin-clavulanate and ciprofloxacin for treatment of women with acute uncomplicated cystitis and used follow-up to evaluate the women for recurrent infection. Ciprofloxacin is in the fluoroquinolone class of antibiotics, a potent and frequently prescribed group that has shown increasing resistance. The trial included 370 women, aged 18 to 45 years. Subjects were randomly assigned to receive amoxicillin-clavulanate (500 mg/125 mg twice daily) or ciprofloxacin (250 mg twice daily) for 3 days and were followed for 4 months.

The researchers found that clinical cure resolution of the symptoms associated with UTI was observed in 93 (58 percent) of 160 women treated with amoxicillin-clavulanate compared with 124 (77 percent) of 162 women treated with ciprofloxacin. Amoxicillin-clavulanate was not as effective as ciprofloxacin even among women infected with bacterial strains susceptible to amoxicillin-clavulanate (65 [60 percent] of 109 women in the amoxicillin-clavulanate group vs. 114
'"/>

Contact: Susan Gregg-Hanson
206-731-4097
JAMA and Archives Journals
22-Feb-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... ZIONA, Israel , August 3, ... TASE: BVXV) today announced it received the statistical analysis of ... vaccine (M-001), administered in the BVX-005 phase II trial which ... future strains which did not exist at the time of ... (flu) strain that caused the epidemic in the ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
Cached News: